170
Participants
Start Date
February 17, 2022
Primary Completion Date
October 1, 2026
Study Completion Date
October 2, 2026
Iptacopan (LNP023)
oral capsules
Placebo
oral capsules
Retina Care Center, Baltimore
Duke Eye Center, Durham
Advanced Research LLC, Deerfield Beach
Retina Center Of South Florida, Delray Beach
Retina Vitreous Associates of Florida, St. Petersburg
Charles Retina Institute, Germantown
Midwest Eye Institute, Indianapolis
Retina Foundation, Dallas
Texas Retina Associates, Fort Worth
Retina Consultants of Houston PA, Houston
Retina Consultants TX Rsrch Ctr, Bellaire
Austin Research Center for Retina, Austin
Southwest Retina Research Center, Durango
Salehi Retina Institute, Huntington Beach
Retina Consultants of Orange County, Fullerton
California Retina Consultants, Santa Barbara
Martel Eye Medical Group, Rancho Cordova
Retinal Consultants Medical Group Inc, Sacramento
Retina Northwest PC, Portland
Novartis Investigative Site, Harbin
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Tianjin
Retina Associates New Orleans, New Orleans
Opthamalic Consultants of Boston, Boston
Envision Ocular LLC, Bloomfield
Emanuelli Research and Development Center LLC, Arecibo
Novartis Investigative Site, London
Novartis Investigative Site, Southampton
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY